The ARHGEF40 Knockout HAP1 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population targeting the human ARHGEF40 gene in the HAP1 cell line. This loss-of-function model disrupts ARHGEF40 expression, providing a versatile tool for studying the contribution of this Rho guanine nucleotide exchange factor (GEF) to cellular processes. The polyclonal format ensures broad representation of edited alleles, making it suitable for population-level biochemical and functional assays.
The HAP1 cell line is a near-haploid human cell model derived from the KBM-7 chronic myeloid leukemia isolate. Its haploid karyotype simplifies genetic manipulation and enables high-efficiency gene targeting, making it a popular choice for forward and reverse genetic screens. HAP1 cells retain key characteristics of the myeloid lineage, allowing interrogation of signaling pathways relevant to leukemia biology, cell migration, and proliferation. This host background provides a clinically relevant context for studying oncogenic signaling and cytoskeletal dynamics.
ARHGEF40 functions as a GEF for the small GTPases RhoA and Cdc42, catalyzing their activation through GDP/GTP exchange. Active RhoA and Cdc42 stimulate downstream effectors, including ROCK and PAK kinases, which phosphorylate LIM kinase and cofilin, leading to dynamic reorganization of the actin cytoskeleton. These events promote actin stress fiber formation, lamellipodial protrusions, and focal adhesion maturation, collectively driving cell adhesion, migration, and proliferation. ARHGEF40 interacts directly with RhoA, Cdc42, and various actin-associated proteins, positioning it as a central node in Rho GTPase signaling.
In the HAP1 leukemia model, ARHGEF40 disruption permits dissection of its role in processes commonly dysregulated in cancer, such as abnormal migration and invasion. The near-haploid background facilitates loss-of-function genetic screens to identify synthetic lethal interactions or suppressors of ARHGEF40-dependent phenotypes, aiding in the discovery of new therapeutic targets for cancers with aberrant Rho pathway activation. This knockout model thus offers a powerful system for linking cytoskeletal regulation to leukemogenesis and metastasis.
Representative applications include western blotting to verify ARHGEF40 protein loss, RhoA/Cdc42 activation assays (e.g., G-LISA), and transwell or wound-healing migration assays. Immunofluorescence analysis can visualize changes in actin stress fibers and focal adhesions, while RT-qPCR and phospho-specific antibodies enable monitoring of downstream mediators such as ROCK, LIMK, and cofilin phosphorylation. Proliferation and drug sensitivity testing can evaluate the impact of ARHGEF40 loss on cell growth and response to Rho pathway inhibitors. This product is ideal for researchers investigating Rho GTPase signaling, cytoskeletal dynamics, cancer cell invasion, and for executing genetic screens to identify migration-related genes. For further technical details, please contact Ascent Research.
